Nuclear Magnetic Resonance Detects Phosphoinositide 3-Kinase/Akt-Independent Traits Common to Pluripotent Murine Embryonic Stem Cells and Their Malignant Counterparts  by Romanska, Hanna M. et al.
Nuclear Magnetic Resonance
Detects Phosphoinositide
3-Kinase/Akt–Independent Traits
Common to Pluripotent Murine
Embryonic Stem Cells and Their
Malignant Counterparts1
Hanna M. Romanska*,2, Stefano Tiziani†,‡,2,
Rachael C. Howe*, Ulrich L. Günther†,
Zulfiqar Gulzar§ and El-Nasir Lalani¶
*Department of Pathology, Division of Cancer Studies,
University of Birmingham, Birmingham, UK; †Henry
Wellcome Building for Biomolecular NMR Spectroscopy
(HWB-NMR), Division of Cancer Studies, University of
Birmingham, Birmingham, UK; ‡Burnham Institute for
Medical Research, La Jolla, CA, USA; §Department of
Urology, Stanford University Medical Centre, Stanford,
CA, USA; ¶Department of Pathology and Microbiology,
Aga Khan University, Karachi, Pakistan
Abstract
Pluripotent embryonic stem (ES) cells, a potential source of somatic precursors for cell therapies, cause tumors after
transplantation. Studies of mammalian carcinogenesis using nuclear magnetic resonance (NMR) spectroscopy have
revealed changes in the choline region, particularly increased phosphocholine (PCho) content. High PCho levels in
murine ES (mES) cells have recently been attributed to cell pluripotency. The phosphoinositide 3-kinase (PI3K)/Akt
pathway has been implicated in tumor-like properties of mES cells. This study aimed to examine a potential link be-
tween the metabolic profile associated with choline metabolism of pluripotent mES cells and PI3K/Akt signaling. We
used mES (ES-D3) and murine embryonal carcinoma cells (EC-F9) and compared the metabolic profiles of 1) pluripo-
tent mES (ESD0), 2) differentiated mES (ESD14), and 3) pluripotent F9 cells. Involvement of the PI3K/Akt pathway
was assessed using LY294002, a selective PI3K inhibitor. Metabolic profiles were characterized in the extracted polar
fraction by 1H NMR spectroscopy. Similarities were found between the levels of choline phospholipid metabolites
(PCho/total choline and PCho/glycerophosphocholine [GPCho]) in ESD0 and F9 cell spectra and a greater-than five-fold
decrease of the PCho/GPCho ratio associated with mES cell differentiation. LY294002 caused no significant change
in relative PCho levels but led to a greater-than two-fold increase in PCho/GPCho ratios. These results suggest that
the PCho/GPCho ratio is a metabolic trait shared by pluripotent and malignant cells and that PI3K does not underlie
its development. It is likely that the signature identified here in a mouse model may be relevant for safe therapeutic
applications of human ES cells.
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Introduction
The capacity of embryonic stem (ES) cells for unlimited self-renewal
and multilineage differentiation has stimulated unprecedented public
and clinical interest as an attractive source of somatic cell precursors
for cell-based therapies. However, despite recent advances in the devel-
opment of ES cell technologies for regenerative medicine, a number of
fundamental questions need to be addressed before ES cells can be used
therapeutically. The main concern relates to their propensity to produce
tumors after transplantation in the absence of any gross chromosomal
abnormalities [1].
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The similarities between stem and cancer cells have long been recog-
nized, and accumulating evidence suggests that stemness and tumori-
genicity might share some phenotypic traits dictated by the same genetic
program [2,3]. Despite a wealth of data on the genotypic and pheno-
typic characteristics of pluripotent self-renewing ES cells, the mecha-
nisms underlying their tumorigenic potential are poorly understood.
Searching for genes specifically expressed in murine ES (mES) cells,
Takahashi et al. [4] demonstrated that the oncogene ERas is expressed
in undifferentiated mES cells and, through its downstream target, the
PI3K/Akt pathway, promotes cell proliferation and tumorigenicity.
Disruption of ERas does not affect the pluripotency of mES cells but
leads to the impairment of cell growth and the ability to produce
tumors in vivo. Proliferative and tumorigenic characteristics of the cells
can be rescued by forced expression of active PI3K/Akt, implicating
the PI3K pathway as a likely mechanism underlying the tumor-like
properties of pluripotent ES cells [4].
Nuclear magnetic resonance (NMR) spectroscopy provides unique
insight into cell metabolism and has recently been recognized as a
powerful tool in phenotypic profiling of human cancers and mam-
malian cell lines, including stem cells and their derivatives [5–10].
In tumors and associated in vitro models, changes in the choline re-
gion of the NMR spectrum arising from an increase of the phospho-
choline (PCho) content have been shown to correlate with the stage
of tumor development and its invasiveness [8,11–13]. Elevated PCho
levels are partially attributed to an increased activity of choline ki-
nase (ChoK) catalyzing the first step in the Kennedy pathway (cyti-
dine diphosphate–choline pathway), an enzyme recently recognized
as both a prognostic marker and a therapeutic target in various types
of human cancers [14–16]. ChoK expression and activity are regu-
lated by a signaling complex with the PI3K pathway as one of its key
components [17,18].
Little is known about the metabolism of ES cells and its changes as
differentiation progresses. The only study available to date showed an
association between mES cell differentiation status and NMR signals
and demonstrated that the NMR profile of pluripotent mES cells is
characterized by a very high PCho content [19]. It is therefore likely
that there is a link among the metabolic profile, PI3K/Akt signaling,
and tumorigenicity of undifferentiated mES cells. As a first step in
examining this potential relationship, we have used 1H NMR spectros-
copy to assess an involvement of the PI3K/Akt pathway in the mecha-
nism underlying development of a putative metabolic fingerprint of
pluripotency/tumorigenicity related to choline metabolism (Figure 1).
We used a model of mES cells (ES-D3) and their malignant coun-
terparts, murine embryonal carcinoma (mEC) cells (EC-F9), a well-
characterized teratocarcinoma cell line [20]. Pluripotent F9 cells show
little spontaneous in vivo or in vitro differentiation and, when injected
into adult syngeneic mice, grow rapidly forming malignant tumors. Be-
cause lineage commitment is associated with loss of ES cell tumorigenic
potential, we compared the genotypic, phenotypic, and metabolic pro-
files of 1) undifferentiated (ESD0) and 2) differentiated (ESD14) mES
cells with those of pluripotent mEC (F9) cells.
Materials and Methods
Cell Lines
Recent characterization of various stem cell lines demonstrated
that major differences in gene expression profiles between pluripotent
cells originate from the strain of the source animal [21]. To minimize
the impact of this variable on our analysis, we chose closely related cell
lines, mES (D3) and mEC (F9), both originating from the 129 strain
mouse. Cell lines were purchased from LGC Promochem (Teddington,
Figure 1. Phosphatidylcholine metabolism. The tinted square highlights the pathway of the choline cycle investigated in the study. CDP-
choline indicates cytidine diphosphate choline; PKC, protein kinase C; PKA, protein kinase A.
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UK, http://www.lgcstandards-atcc.org). Cell pluripotency was main-
tained under standardized conditions recommended by the manufac-
turer. The differentiation protocol for the mES cells did not involve
any chemical inducer.
Cell Culture
D3 cells were routinely cultured on 0.1% (vol/vol) gelatin-coated
100-mm tissue culture dishes at a seeding density of 2 × 106 cells per
dish, in complete Dulbecco’s modified Eagle medium (high-glucose
DMEM [Invitrogen, Paisley, UK, http://www.invitrogen.com], 2 mM
L-glutamine [Sigma-Aldrich, http://www.sigmaaldrich.com], Primocin
[100 μg/ml; AutogenBioclear, Calne, UK, http://www.autogenbioclear.
com], 0.1 mM 2-mercaptoethanol [Sigma-Aldrich]) supplemented
with 15% (vol/vol) KnockOut Serum Replacement (Invitrogen) and
leukemia inhibitory factor (LIF, ESGRO, 1000 U/ml; Millipore,
Livingston, UK, http://www.millipore.com). Undifferentiated mES
cells (ESD0) at passage 10 to 14 were used. Differentiation of the cells
was induced through embryoid body (EB) formation by partial trypsin
digestion (0.05% [vol/vol] trypsin/0.53 mM EDTA in 0.1 M PBS
without Ca2+ or Mg2+; 2% [vol/vol] chicken serum [Sigma-Aldrich]).
EBs were cultured in nonadherent bacterial-grade Petri dishes in
complete DMEM supplemented with 10% (vol/vol) batch-tested FBS
(Sigma-Aldrich) for 7 days, then transferred to 0.1% (vol/vol) gelatin-
coated dishes and grown as adherent cultures for a further 7 days
(ESD14) in complete DMEM. The day 14 time point (ESD14), as a
differentiation stage of mES cells, was chosen as arbitrary long growth
interval based on previous reports demonstrating loss of pluripotency
and an almost complete decline in Oct 4 expression in mES (D3) cells
cultured for 14 days in the absence of LIF [22].
F9 cells were cultured on 0.1% (vol/vol) gelatin-coated tissue cul-
ture dishes (2 × 106/100-mm plate) in complete DMEM supple-
mented with 10% (vol/vol) batch-tested FBS (Sigma-Aldrich).
When 80% confluent, the cells were collected for analyses. All cul-
tures were maintained at 37°C in 10% (vol/vol) carbon dioxide in
a humidified tissue culture incubator, and medium was replenished
every 24 hours.
In inhibition experiments, 10 μM LY294002 (Merck Chemicals Ltd,
Nottingham, UK, http://www.merckbiosciences.co.uk) or vehicle
(Me2SO) alone was added to the medium, and cells were incubated for
24 hours before harvesting.
Reverse Transcription–Polymerase Chain Reaction
Total RNAwas extracted from the cells using Qiagen RNAMiniprep
Kit (Qiagen, Crawley, UK, http://www1.qiagen.com), as recommended
by the manufacturer. Reverse transcription (RT) and polymerase chain
reaction (PCR) with template RNA (0.1 μg per reaction) were carried
out using One-Step RT-PCR Kit (Qiagen). The primer sequences were
as follows:
alfa-fetoprotein (AFP):
forward 5′-caatctggaagaagaattgc-3′;aps
reverse 5′-acagatccttgtggaagatg-3′ (35 cycles, 428 bp);
T-Brachury (TBra):
forward 5′-atgccaaagaaagaaacgac-3′;
reverse 5′-agaggctgtagaacatgatt-3′ (35 cycles, 835 bp);
neurofilaments-68k (NF-68):
forward 5′-tagagcgcaaagattacctgaag-3′;
reverse 5′-ttgacgttaaggagatcctggta-3′ (35 cycles, 406 bp);
ERas:
forward 5′-aaaaaagcaggctggggaatggctttgccta-3′;
reverse 5′-agaaagctgggtcaaagatcttcaggctacag-3′ (35 cycles, 750 bp) and
β-actin:
forward 5′-aggtcatcactattggcaac-3′;aps
reverse 5′-caaagaaagggtgtaaaacg-3′ (27 cycles, 431 bp).aps
PCR amplification was performed in an Eppendorf Mastercycler
(Eppendorf, Cambridge, UK, http://www.eppendorf.co.uk). PCR prod-
ucts were subjected to electrophoresis in 1.5% (wt/vol) Agarose gel in
Tris-acetate EDTA buffer and stained with ethidium bromide. Gel
images were captured using an ultraviolet ChemiGenius Bioimaging Sys-
tem (Gene-Flow Systems, Fradley, UK, http://www.geneflow.co.uk).
Western Blot Analysis
Cells grown in 100-mm culture plates were washed with ice-cold
PBS, lysed in 0.5 ml of cold lysis buffer (20 mM Tris-HCl, pH 7.5,
150 mMNaCl, 1 mMNa2EDTA. 1 mM EGTA, 1% [vol/vol] Triton,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM
Na3VO4, 1 μg/ml leupeptin 1 mM PMSF [Cell Signaling, Hitchin,
UK, http://www.cellsignal.com]) for 5 minutes on ice, scraped, and
sonicated. The lysates were then cleared by centrifugation at 14,000g
for 10minutes at 4°C. Equal amounts of cell lysate proteins (30μg)were
resolved by 10% SDS–polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulosemembrane, blocked, and probed with the follow-
ing antibodies: rabbit anti–Oct 4 (1:1000; Santa Cruz, Heidelberg,
Germany, http://www.scbt.com), rabbit anti-Akt (1:1000; Cell Signaling),
rabbit anti–phospho (S473) Akt (1:1000; Cell Signaling), and mouse
anti–β-actin (1:4000; Abcam, Cambridge, UK, http://www.abcam.
com).Membranes were then washed and incubated with secondary anti-
bodies conjugated with donkey antirabbit or antimouse horseradish per-
oxidase (1:5000; GE Healthcare, Chalfont St Giles, UK, http://www.
gehealthcare.com) and visualized by enhanced chemiluminescence ap-
plied following the manufacturer’s instructions (GE Healthcare). Blots
were developed using an automated Kodak Film Developer System
(Kodak, Hemel Hempstead, UK, http://www.kodak.com).
NMR Sample Preparation
Cells grown to 70% to 80% confluence were trypsinized, washed
twice in ice-cold PBS, and harvested by centrifugation. Three replicate
samples of approximately 15 × 106 cells each were prepared per time
point and cell line. The pellets were immediately frozen in liquid nitro-
gen and stored at −80°C. The extraction of intracellular metabolites
from cell pellets was performed using a modified Bligh-Dyer procedure
[23]. Samples were dried overnight in a centrifugal vacuum concentra-
tor. The dried polar extracts were redissolved in 90% H2O/10% D2O
(GOSS Scientific Instruments Ltd, Essex, UK) prepared as 100 mM
phosphate buffer (pH 7.0), containing 0.5 mM sodium 3-(trimethylsilyl)-
propionate-2,2,3,3-d4 (TMSP; Cambridge Isotope Laboratories, Inc,
Andover, MA) as an internal chemical shift reference.
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NMR Data Acquisition
A 500-MHzDRX Bruker spectrometer equipped with a cryogenically
cooled probe was used for one-dimensional 1H and two-dimensional
1H J-resolved ( J-RES) spectra. In both cases, the water resonance was
suppressed using excitation sculpting [24].One-dimensional spectra were
acquired using a 30° pulse, with a 5-kHz spectral width, a relaxation delay
of 15 seconds, and 256 transients. Two-dimensional J-RES spectra were
collected using a double spin-echo sequence with 32 transients per in-
crement and 64 increments. Strong coupling artifacts were suppressed
by phase cycling [25].
NMR Data Processing and Postprocessing
NMR data were processed using NMRLaB [26] in the MATLAB
(TheMathWorks, Natick,MA, http://www.mathworks.com) program-
ming environment. Before Fourier transformation, two-dimensional
J-RES spectra weremultiplied by a combined sine bell/exponential win-
dow function in the direct dimension and by a sine bell function in
the incremented dimension [27]. After apodization, two-dimensional
J-RES spectra were tilted in the frequency space by 45°, and skyline pro-
jections were calculated using NMRLaB to simplify one-dimensional
spectra and reduce peak congestion. One-dimensional and projected
J-RES spectra were aligned, signals arising from residual solvents, and
TMSPwere excluded, and the total spectral area was normalized to unity.
NMRs of metabolites were assigned and quantified using the Chenomx
NMR Suite (version 5.1; Chenomx Inc, Edmonton, Canada). The final
concentration of selected metabolites was adjusted according to the co-
efficients of total spectral area normalization obtained from TMSP peak
area–normalized spectra.
Statistical Analysis
The concentrations of metabolites are reported as mean values ± SD.
Statistical comparison between data obtained from undifferentiated and
differentiated ES and F9 cells was performed using an unpaired Stu-
dent’s t-test (statistical significance: *P < .05, **P < .01, and ***P < .001).
Results
Expression of Markers of Pluripotency and Differentiation
To assess the status of pluripotency and/or differentiation of ESD0,
ESD14, and F9 cells, we used a panel of commonly accepted markers.
Oct 4. Oct 4 is a mammalian POU (pit, oct, unc are the subgroup
domain transcription factors of homeodomain proteins) transcription
factor expressed in the early embryo whose transcriptional activity is
tightly controlled throughout embryogenesis. Oct 4 plays a critical role
in maintaining pluripotency of ES cells [28]. As its down-regulation is
required for differentiation into somatic lineages [29], Oct 4 is widely
regarded as a marker of pluripotent stem cells.
Immunoblot analysis showed strong expression of the protein in both
ESD0 and F9 and its absence from ESD14 cells (Figure 2a).
Lineage markers. Withdrawal of LIF from the culture medium and
cell aggregation into EBs leads to ES cell differentiation and lineage
commitment [30]. This is characterized by an up-regulation of tran-
script markers of early germ layers. Expression of T-Brachury (TBra),
alfa-fetoprotein (AFP), and neurofilaments-68k (NF-68), markers of
mesoderm, endoderm, and ectoderm, respectively, was studied. In un-
differentiated ESD0 and F9 cells, transcripts of TBra, AFP, and NF-68
were not detected. Differentiated ESD14 cells expressed all three line-
age markers (Figure 2b).
The inverse relationship between Oct 4 and lineage markers’ expres-
sion in the three cell lines confirmed the pluripotency of ESD0 and F9
cells and its loss associated with mES cell differentiation (ESD14).
PI3K/Akt Signaling
Murine ES cells maintain a pluripotent phenotype when cultured in
the presence of LIF, which acts through the gp130 receptor component
and activates the PI3K/Akt cascade [31,32]. In F9 cells, the PI3K/Akt
pathway is activated constitutively [33]. Akt is a mediator of many
events downstream of PI3K, and its phosphorylation at Ser473 and/
or Thr308 is associated with PI3K activity. We compared the involve-
ment of PI3K/Akt to cell pluripotency between normal and malignant
mES cells using antibodies to phospho-Akt (Ser473) (pAkt).
The steady-state levels of PI3K/Akt activity differed between cell
lines, with basal levels of pAkt being much higher in F9 cells. In mES
cells, a marked decrease of the level of Akt phosphorylation followed
cell differentiation (Figure 3a).
Akt is a downstream effector of ERas/PIK3 pathway implicated in
tumor-like properties of mES cells [4]. Using RT-PCR, we examined
the level of ERas transcripts. Eras showed a gradient of expression from
the highest in F9 cells to the lowest in ESD14 cells (Figure 3b), reflect-
ing the pattern observed for pAkt (Figure 3a). These observations
are consistent with the suggested role of ERas/PI3K in the functional
phenotype of the cells.
NMR Spectra
A NMR-based approach was used to search for traits common to
pluripotency and tumorigenicity that would encompass the complexity
of cell metabolism. We monitored and recorded the changes associated
Figure 2. Pluripotency and differentiation. (a) Western blot analysis
for Oct 4 shows strong expression in ESD0 and F9 cells and its ab-
sence from ESD14 cells. Expression of β-actin confirms equal load-
ing. (b) Semiquantitative RT-PCR analysis shows expression of
transcripts of TBra, AFP, and NF-68, markers of mesoderm, endo-
derm, and ectoderm, respectively, in differentiated ESD14 cells. In
contrast, these transcripts are not detected in undifferentiated ESD0
and F9 cells. β-actin was used as loading control.
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with the loss of pluripotency of mES cells in comparison to the meta-
bolic profile of their pluripotent malignant counterparts. Figure 4a
shows a representative one-dimensional NMR spectrum of a ESD0 cell
extract. The spectrum is dominated by the resonances of amino acids
(e.g., valine, leucine and isoleucine, alanine, glycine, and glutamate),
intermediate metabolites of the glycolytic pathway (e.g., lactate), and
other compounds related to energy metabolism (e.g., AMP, Figure 4a).
An expanded section of the 1H NMR spectrum relates to choline
metabolism, that is, choline, PCho, and GPCho resonances, as shown
in Figure 4b (3.195-3.245 ppm). The results demonstrate that the con-
centration of PCho in pluripotent mES cells (ESD0) was noticeably
higher than that in their differentiated progenies (ESD14) and com-
parable to the PCho content of F9 cells. The relative contribution of
PCho to the total choline pool and the PCho/GPCho ratios are de-
picted in Figure 5, a and b, respectively. Data show that the choline
phospholipid profile of mES cells changed considerably with cell dif-
ferentiation. In ESD14 cells, an overall decrease of choline metabolites
was observed (Figure 4b). In addition, the PCho/GPCho ratio showed
a dramatic (approximately five-fold) decrease as compared with that of
ESD0 cells (Figure 5b).
To explore a potential contribution of PI3K/Akt signaling to the
metabolic signature of pluripotent normal and malignant cells, we
measured the concentrations of choline-related metabolites in cells
cultured in the presence of LY294002, a specific PI3K inhibitor (Fig-
ure 3c). Figure 5a shows that in cells incubated with LY294002,
there was an observable but not significant increase in the relative
concentration of PCho. However, in both pluripotent cell lines, in-
hibition of PI3K activity caused a greater than two-fold increase in
the PCho/GPCho ratios, suggesting that PI3K/Akt contributes to the
choline cycle and PCho synthesis through mechanisms other than
Figure 4. NMR spectra. (a) Representative 1H NMR spectrum of a mES cell extract. Predominant metabolite resonances are labeled on the
spectrum. Val indicates valine; Ile, isoleucine; Leu, leucine; Lac, lactate; Ala, alanine; Gluc, glucose; Cr, creatine; AMP, adenosine mono-
phosphate. (b) Section of 1H NMR spectra (expanded between 3.195 and 3.245 ppm) of mES cells at day 0 with (ESD0 + LY, red line) and
without (ESD0, blue line) LY treatment, mES cells after 14 days of growth (cyan line) and teratocarcinoma cell line F9 with (F9+ LY, black line)
and without (F9, green line) LY294002 treatment.
Figure 3. PI3K/Akt signaling. (a)Western blot analysis for pAkt shows
its strongest expression in F9 cells. For mES cells, Akt phosphory-
lation is high in ESD0 cells and decreases with cell differentiation
(ESD14). (b) Semiquantitative RT-PCR for Eras transcript shows
its strongest expression in F9 cells and weakest in differentiated
ESD14 cells. (c) Treatment of cells with 10 μMLY294002 for 24 hours
caused an almost complete attenuation of Akt phosphorylation.
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the Kennedy pathway. Addition of vehicle alone to the cell culture
medium did not have any significant effect on NMR spectra (Figure 5,
a and b).
Discussion
Pluripotent ES cells have a propensity to produce tumors after trans-
plantation, and identification of markers of their tumorigenic potential
is of prime importance for their prospective therapeutic use. Here, we
provide evidence that metabolic profiling of pluripotent mES cells and
their malignant counterparts by 1H NMR spectroscopy identifies fea-
tures in the choline region of the spectra observed previously in cancer
cells and attributed to malignancy [6,11]. Loss of pluripotency and cell
lineage commitment is associated with loss of this distinct “cancer-like”
metabolic fingerprint.
PCho is a precursor of phosphatidylcholine (PtdCho), the key phos-
pholipid of biologic membranes. An increase in the intracellular pools
of PtdCho is required for membrane synthesis and, thus, is believed to
be associated with cell proliferation [34].
Our results show that NMR spectra of ESD0 and F9 cells were
dominated by high PCho contents and that the rapid growth char-
acteristics of pluripotent ES cells could account for these observed ele-
vated PCho levels. However, comparative studies of human normal and
malignant epithelial cells with similar doubling times demonstrated that
accelerated cell growth alone cannot justify the high concentrations of
choline phospholipid metabolites, suggesting a close link between the
rise in PCho metabolism and malignancy [11,35]. In addition to an
increase in phospholipid biosynthesis and breakdown, malignant trans-
formation is also associated with alterations in relative concentrations of
choline-containing metabolites. In particular, “a glycerophosphocholine
to phosphocholine switch” is proposed as a hallmark of malignant
phenotype [8,11–13]. Our results show an overall decline of choline
metabolites and, more significantly, a decrease of the relative concen-
tration of PCho in differentiated (ESD14) mES cells and are in agree-
ment with the recently reported NMR profiling of the same mES cell
line [19]. Comparing the PCho content of pluripotent mES cells with
the database of transformed somatic cell lines, Jansen et al. [19] have
implied that mES and cancer cells may share a choline metabolome.
Our study was carried out in a model system of closely related cell lines
to minimize the possible impact of the cell genetic background on their
metabolic profiles and its results provide support for this hypothesis.
The data point at striking similarities between the choline regions of
pluripotent mES and F9 cell spectra and demonstrate a greater-than
five-fold decrease of PCho/GPCho ratio in response to cell differen-
tiation. It is tempting to speculate that this inversion of the GPCho
to PCho switch reflects loss of mES cell tumorigenicity and reversal
to a “normal” phenotype.
We investigated the potential link between distinct features of cho-
line phospholipid metabolism shared by pluripotent mES and F9 cells
and the PI3K/Akt pathway. The PI3K/Akt signaling, long recognized
as a survival pathway in mammalian tumorigenesis, is also a known
regulator of self-renewal in various stem cell systems [31,36–38]. Re-
cent work by Takahashi et al. [4] has provided evidence that signaling
through the PI3K pathway promotes tumorigenicity of pluripotent
mES cells. The PI3K pathway has also been associated with choline
phosopholipid metabolism and shown to mediate Ras-induced activa-
tion of ChoK [18], the key enzyme of the dominant pathway for PCho
[34], that is strongly implicated in mammalian carcinogenesis [14].
Although the regulation of PI3K activity in ES cells, as well as the down-
stream signaling targets, differ from those in somatic cells [31,32,36–
39], a link between PI3K activity, tumorigenicity of pluripotent cells,
and PCho biosynthesis seemed very plausible. Our data show that loss
of pluripotency is associated with decreases in both PCho levels and
PI3K/Akt activity. However, inhibition of PI3K in pluripotent mES
and F9 cells did not have any significant effect on relative PCho con-
centration and, in both cell lines, caused a similar, greater-than two-fold
increase in the PCho/GPCho ratio. These results show that in our
in vitro model, the PI3K/Akt signaling pathway is not involved in the
Figure 5. Choline phospholipid metabolites. (a) PCho and total choline (Tot choline) ratios. PCho / (GPCho + PCho + Cho) for mES cells at
day 0 with (ESD0 + LY) and without (ESD0, ESD0V) LY294002 treatment, mES cells after 14 days of differentiation (ESD14) and terato-
carcinoma cells with (F9 + LY) and without (F9, F9V) LY treatment. Differentiation is associated with a significant reduction of PCho/Tot
(total) choline (ESD0 vs ESD14, P < .05). In both cell lines, treatment with LY294002 caused observable but not significant increases in the
PCho/Tot choline ratio. Vehicle alone (ESD0V; F9V) did not have any impact on PCho/Tot choline ratios. ESD0V and F9V— cells treated with
vehicle alone. (b) PCho and GPCho ratios. PCho/GPCho for mES cells at day 0 with (ESD0 + LY) and without (ESD0, ESD0V) LY294002
treatment, mES cells after 14 days of differentiation (ESD14) and teratocarcinoma cells with (F9 + LY) and without (F9, F9V) LY294002
treatment. In differentiated mES cells, there is a significant decrease in PCho/GPCho ratios compared with undifferentiated cells (ESD0
vs ESD14, P < .0001). In both pluripotent cell lines (ESD0 and F9), treatment with LY294002 caused a significant (P < .001) increase in
PCho/GPCho ratios. Vehicle alone (ESD0V and F9V) did not have any impact on PCho/GPCho concentrations.
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de novo synthesis of PCho and PtdCho through the Kennedy pathway,
ruling out the PI3K/PCho as a mechanism underlying the putative
metabolic signature of pluripotency/tumorigenicity.
ChoK activation may be stimulated by a number of other mecha-
nisms including availability of choline [40], phospholipase D [18], pro-
tein kinase C, or protein kinase A [17]. Interestingly, aberrant activities
of these enzymes have been associated with malignant transformation
of mammalian somatic cells and human cancer [41–43]. Furthermore,
PCho is a product of both PtdCho biosynthesis and catabolism, and be-
sides increased activity of ChoK, its accumulation may also be a conse-
quence of an activation of hydrolytic enzymes of the choline cycle [34].
In particular, up-regulation of PtdCho-specific phospholipase C (PC-
PLC) catalyzing the breakdown of PtdCho to PCho has recently been
reported in human ovarian cancer and demonstrated to correlate with
tumor progression [13,44]. Thus, it seems that alternative or combined
activation of various pathways of phospholipid metabolism is respon-
sible for the development of the distinct metabolic trait observed in our
study. Whatever the mechanism, our results demonstrate that PI3K/
Akt, thus far the only mechanism positively identified as a link between
pluripotency and tumorigenicity, does not underlie the metabolic sig-
nature believed to reflect tumorigenic potential of pluripotent cells.
Development of molecular fingerprints of stemness/tumorigenicity
may have implications reaching far beyond regenerative medicine. Ac-
cording to the cancer stem (CS) cell hypothesis, recently revived with a
new impetus, these cancer-initiating cells share many features with nor-
mal stem cells, and their biology is governed by self-renewal pathways
[45]. A comprehensive analysis by Wong et al. [46] supports this hy-
pothesis and demonstrates that a transcriptional ES cell–like program is
indeed reactivated in multiple epithelial cancers and may be important
for the CS cell function. Because CS cells are believed to be responsi-
ble not only for sustained cancer progression but also for the failure of
eradicating therapies [47], considerable effort is being made in the
search for a fingerprint of stemness common to both normal and ma-
lignant stem cells. Exhaustive data generated by gene and protein ex-
pression analyses are inconsistent and, thus far, do not provide the basis
for a molecular definition of stemness [48,49]. It seems that integra-
tion of various approaches, including metabolomics reflecting the out-
come of multiple molecular signaling pathways [50], is required for
establishing the criteria for identification of true stem cells. Our study
contributes to this worldwide search and suggests that PCho and PCho/
GPC levels might provide surrogate metabolic markers of stemness/
tumorigenicity common to pluripotent stem and cancer cells. Under-
standing of the mechanisms underlying the development of this signa-
ture, demonstration of its potential existence in human ES cells, as well
as in vivo validation require further studies.
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